Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
FEBS Lett ; 473(1): 85-8, 2000 May 04.
Article in English | MEDLINE | ID: mdl-10802065

ABSTRACT

Long-term caloric restriction in rodents is known to decrease levels of oxidative damage, which may contribute to an 'anti-ageing' effect. We show here that a shorter period (10 months) of caloric restriction had only small effects on levels of oxidative DNA and protein damage in the livers of mice, but completely attenuated increased oxidative damage caused by the carcinogen clofibrate. Since clofibrate is thought to exert its actions by increasing oxidative damage, our data suggest that 10 months of caloric restriction can increase the resistance of tissues to agents inducing oxidative stress. This may be an important factor in explaining how caloric restriction decreases cancer incidence.


Subject(s)
Carcinogens/pharmacology , Clofibrate/pharmacology , Energy Intake , Food Deprivation , Liver/drug effects , Oxidative Stress/drug effects , 8-Hydroxy-2'-Deoxyguanosine/analogs & derivatives , Acyl-CoA Oxidase , Animals , Body Weight/drug effects , Carcinogens/antagonists & inhibitors , Cell Nucleus/drug effects , Cell Nucleus/genetics , Cell Nucleus/metabolism , Clofibrate/antagonists & inhibitors , DNA Damage/drug effects , DNA Damage/genetics , DNA, Mitochondrial/drug effects , DNA, Mitochondrial/genetics , Guanine/analogs & derivatives , Guanine/analysis , Liver/cytology , Liver/enzymology , Liver/metabolism , Male , Mice , Mitochondria/drug effects , Mitochondria/metabolism , Nuclear Proteins/metabolism , Organ Size/drug effects , Oxidation-Reduction/drug effects , Oxidoreductases/metabolism , Peroxisomes/drug effects , Peroxisomes/metabolism , Time Factors
2.
J Cell Biochem ; 68(3): 298-308, 1998 Mar 01.
Article in English | MEDLINE | ID: mdl-9518257

ABSTRACT

Phosphoenolpyruvate carboxykinase (PEPCK) exerts a glyceroneogenic function in adipocytes in which transcription of its gene is increased by unsaturated fatty acids and fibrates. We used cultured rat adipose tissue fragments and 3T3-F442A adipocytes to show that the antidiabetic thiazolidinedione BRL 49653, a ligand and an activator of the gamma isoform of peroxisome proliferator activated receptors (PPARgamma), is a potent inducer of PEPCK mRNA. In 3T3-F442A adipocytes, the effect of BRL 49653 is rapid and concentration dependent, with a maximum reached at 1 microM and a half-maximum at 10-100 nM. PEPCK mRNA is similarly induced by the natural ligand of PPARgamma, the 15-deoxy-delta(12-14) prostaglandin J2. These observations strongly suggest that PPARgamma is a primary regulator of PEPCK gene expression in adipocytes. Dexamethasone at 10 nM repress induction of PEPCK mRNA by 1 microM BRL 49653, 0.32 mM oleate, or 1 mM clofibrate, in a cycloheximide-independent manner. The antiglucocorticoid RU 38486 prevents dexamethasone action, demonstrating involvement of the glucocorticoid receptor. Stable transfectants of 3T3-F442A adipocytes bearing -2100 to +69 base pairs of the PEPCK gene promoter fused to the chloramphenicol acetyltransferase (CAT) gene respond to 1 microM BRL 49653 or 1 mM clofibrate by a large increase in CAT activity, which is prevented by the simultaneous addition of 10 nM dexamethasone. Hence, in adipocytes, glucocorticoids act directly through the 5'-flanking region of the PEPCK gene to repress, in a dominant fashion, the stimulation of PEPCK gene transcription by thiazolidinediones and fibrates.


Subject(s)
Adipocytes/enzymology , Fatty Acids/pharmacology , Genes/genetics , Glucocorticoids/pharmacology , Hypoglycemic Agents/pharmacology , Phosphoenolpyruvate Carboxykinase (GTP)/drug effects , Phosphoenolpyruvate Carboxykinase (GTP)/genetics , Thiazolidinediones , 3T3 Cells/chemistry , 3T3 Cells/cytology , Adipocytes/chemistry , Adipocytes/metabolism , Adrenergic beta-Agonists/pharmacology , Animals , Clofibrate/antagonists & inhibitors , Clofibrate/pharmacology , Dexamethasone/pharmacology , Enzyme Induction/drug effects , Enzyme Induction/genetics , Fatty Acids/antagonists & inhibitors , Gene Expression Regulation, Enzymologic/drug effects , Genes/drug effects , Genes/physiology , Hypoglycemic Agents/antagonists & inhibitors , Isoproterenol/antagonists & inhibitors , Isoproterenol/pharmacology , Male , Mice , Protein Biosynthesis , Proteins/drug effects , RNA, Messenger/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptors, Cytoplasmic and Nuclear/physiology , Regulatory Sequences, Nucleic Acid/drug effects , Regulatory Sequences, Nucleic Acid/genetics , Rosiglitazone , Thiazoles/antagonists & inhibitors , Thiazoles/pharmacology , Trans-Activators/pharmacology , Transcription Factors/physiology
3.
Biochim Biophys Acta ; 1256(3): 327-33, 1995 Jun 06.
Article in English | MEDLINE | ID: mdl-7786895

ABSTRACT

Using primary cultures of rat hepatocytes on a matri-gel, effects of peroxisome proliferator and omega-hydroxydodecanoic acid on cellular levels of acyl-CoA oxidase and CYP4A have been studied to determine the hormonal influence in serum-free media. Peroxisomal acyl-CoA oxidation, microsomal CYP4A content and laurate omega-hydroxylation were increased in rat hepatocytes by the addition of 100 microM clofibrate or Wy14,643 for two days. omega-Hydroxydodecanoic acid (100 microM) also increased peroxisomal acyl-CoA oxidation, but had no clear effect on microsomal CYP4A level and laurate omega-hydroxylation. CYP4A-mediated laurate omega-hydroxylation in hepatocytes was suppressed by the addition of pituitary growth hormone (0.05 mU/ml), but was not altered by the addition of triiodothyronine (30 nM). In contrast, clofibrate-mediated induction of acyl-CoA oxidase activity was decreased by the addition of either one of the hormones in hepatocytes. Suppression by those hormones was also observed with omega-hydroxydodecanoic acid-mediated induction of acyl-CoA oxidase activity. These results indicate the possibility that GH and T3 exert the suppressive effects on peroxisomal acyl-CoA oxidation through plural mechanisms with and without the alteration of CYP4A levels in livers.


Subject(s)
Clofibrate/antagonists & inhibitors , Cytochrome P-450 Enzyme Inhibitors , Fatty Acids/metabolism , Growth Hormone/pharmacology , Liver/drug effects , Mixed Function Oxygenases/antagonists & inhibitors , Oxidoreductases/antagonists & inhibitors , Triiodothyronine/pharmacology , Acyl-CoA Oxidase , Animals , Cells, Cultured , Cytochrome P-450 CYP4A , Female , Liver/metabolism , Male , Microbodies/drug effects , Microbodies/metabolism , Microsomes/drug effects , Microsomes/metabolism , Oxidation-Reduction , Pyrimidines/pharmacology , Rats , Rats, Sprague-Dawley
4.
Metabolism ; 44(2): 166-71, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7869911

ABSTRACT

In an effort to identify the effects of the 3-carbon compound pyruvate on free radical production, we measured hepatic total peroxisomal beta-oxidation and catalase activity and the production of lipofuscin-like products in male Sprague-Dawley rats consuming an adequate diet supplemented with pyruvate, vitamin E, or the peroxisome proliferator and free radical enhancer clofibrate for 22 days (n = 5 in each group). Clofibrate feeding induced hepatomegaly, a fivefold increase in total peroxisomal beta-oxidation activity, and a threefold increase in hepatic lipofuscin-like products (P < .05). Pyruvate but not vitamin E inhibited the increase in liver size by 70% (P < .05). Both pyruvate and vitamin E completely inhibited clofibrate-induced increases in lipofuscin-like products (P < .05). Pyruvate but not clofibrate or vitamin E increased plasma concentrations of the nitric oxide metabolites nitrite and nitrate (P < .05). We conclude that with clofibrate-induced peroxisomal proliferation and free radical production, pyruvate will inhibit peroxisomal proliferation and free radical production, inhibit free radical-induced lipid peroxidation, and enhance metabolism of nitric oxide.


Subject(s)
Clofibrate/antagonists & inhibitors , Liver/metabolism , Microbodies/drug effects , Pyruvates/administration & dosage , Vitamin E/administration & dosage , Animals , Body Weight , Catalase/analysis , Diet , Drug Interactions , Free Radicals/analysis , Lipofuscin/analysis , Liver/ultrastructure , Male , Microbodies/physiology , Microscopy, Electron , Organ Size , Oxidation-Reduction , Pyruvic Acid , Rats , Rats, Sprague-Dawley
5.
J Neurol ; 219(2): 107-16, 1978 Oct 25.
Article in English | MEDLINE | ID: mdl-81288

ABSTRACT

Myotonia was induced in rats with clofibrate given in daily subcutaneous injections of 0.4 g/kg. The first myotonic discharges were recorded electromyographically from the extensor digitorum longus, tibialis anterior, and gastrocnemius muscles after 4 days on clofibrate, but from the soleus not until after 11 days. Clofibrate induced myotonic activity in chronically denervated muscle also. During repetitive nerve stimulation the electrical response of the muscle was declining in all myotonic rats. It did so also when repetitive stimulation was applied directly to the muscle, which would seem to suggest a myotonic defect as the cause. Several drugs were tested and diphenylhydantoin proved to inhibit myotonia most effectively. Animals on an extended clofibrate schedule (12 weeks) had ECG abnormalities resembling those seen in patients with myotonic dystrophy.


Subject(s)
Clofibrate/toxicity , Myotonia/chemically induced , Action Potentials , Animals , Clofibrate/antagonists & inhibitors , Disease Models, Animal , Electric Stimulation , Male , Muscles/physiopathology , Myotonia/drug therapy , Myotonia/physiopathology , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...